StemCells (STEM) +8.6% premarket on top of yesterday's 21% spike after the smallcap company...

|By:, SA News Editor

StemCells (STEM) +8.6% premarket on top of yesterday's 21% spike after the smallcap company unveiled a plan to provide data from a Phase I/II clinical trial testing its stem-cell therapy to be used in the treatment of chronic spinal-cord injuries at the International Spinal Cord Society's annual scientific meeting.